Literature DB >> 20060322

Combined treatment with chemokine receptor 5 blocker and cyclosporine induces prolonged graft survival in a mouse model of cardiac transplantation.

Li Jun1, Zhang Kailun, Xie Aini, Xu Lei, Wang Guohua, Wang Sihua, Ye Ping, Sun Tucheng, Jiang Xionggang, Chen Wenwei, Xia Jiahong.   

Abstract

BACKGROUND: Inhibition of chemokine receptor 5 (CCR5), a chemokine receptor expressed on activated T cells, is efficacious in modulating inflammation and immunity as well as in patients with human immunodeficiency virus infection. This study examined the effect and mechanism of CCR5 blockade in combination with cyclosporine in prolonging cardiac allograft survival in mice.
METHODS: Hearts from BALB/c mice were transplanted into C57BL/10 recipients. They were administrated with anti-CCR5 antibody (Ab) or control Ab and cyclosporine or phosphate-buffered (PBS) saline, respectively. To investigate the role of regulatory cells, naïve mice (secondary recipients) underwent adoptive transfer of splenocytes from anti-CCR5 Ab plus cyclosporine-treated recipients and cardiac allograft transplantation.
RESULTS: Compared with recipients treated with control Ab plus PBS, allografts treated with anti-CCR5 Ab and cyclosporine showed significantly prolonged survival (p < 0.001), markedly decreased CD4+ and CD8+ T cells (p < 0.005), and increased frequency of CD4+CD25+Foxp3+ regulatory cells (23.98% +/- 1.55% vs 6.30% +/- 0.57%, p < 0.005). Adoptive transfer of CD4+CD25+ splenocytes from anti-CCR5 Ab plus cyclosporine-treated recipients induced significantly prolonged survival in secondary recipients (p < 0.01 vs adoptive transfer from naïve mice and recipients depleted of CD25+ cells).
CONCLUSIONS: CCR5 blockade combined with cyclosporine is effective in protecting the cardiac allograft in a robust murine model. This effect is partly mediated by regulatory cell recruitment and control of effector cell infiltration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20060322     DOI: 10.1016/j.healun.2009.09.019

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  2 in total

Review 1.  Clinical use of CCR5 inhibitors in HIV and beyond.

Authors:  Bruce L Gilliam; David J Riedel; Robert R Redfield
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

2.  The effect of the CCR5-delta32 deletion on global gene expression considering immune response and inflammation.

Authors:  Gero Hütter; Martin Neumann; Daniel Nowak; Stefan Klein; Harald Klüter; Wolf-K Hofmann
Journal:  J Inflamm (Lond)       Date:  2011-10-26       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.